Celldex Therapeutics Inc
CLDX
查看详细走势图
23.760USD
+1.180+5.23%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.58B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.23%
5天
-3.41%
1月
-14.41%
6月
+12.02%
今年开始到现在
-12.52%
1年
+5.74%
查看详细走势图
TradingKey Celldex Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Celldex Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名69/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价52.31。中期看，股价处于平稳状态。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Celldex Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Celldex Therapeutics Inc亮点
亮点风险
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
业绩高增长
公司营业收入稳步增长，连续3年增长197.84%
业绩增长期
公司处于发展阶段，最新年度总收入7.02M美元
利润高增长
公司净利润处于行业前列，最新年度总收入7.02M美元
估值高估
公司最新PE估值-7.02，处于3年历史高位
机构加仓
最新机构持股73.56M股，环比增加2.11%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值40.78K
活跃度增加
近期活跃度增加，过去20天平均换手率0.51
分析师目标
根据
16
位分析师
买入
评级
52.308
目标均价
+115.52%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Celldex Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Celldex Therapeutics Inc简介
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
公司代码CLDX
公司Celldex Therapeutics Inc
CEOMarucci (Anthony S)
网址https://celldex.com/
相关品种
